U. S. Securities and Exchange Commission
                         Washington, D. C.  20549


                                FORM 10-QSB


[X]  QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
     EXCHANGE ACT OF 1934

     For the quarterly period ended June 30, 2005

[ ]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934

     For the transition period from                  to
                                    -----------------   ---------------

                       Commission File No. 0-49655
                                           -------


                         LIPIDVIRO TECH, INC.
                         --------------------
     (Exact Name of Small Business Issuer as specified in its Charter)


            Nevada                                     87-0678927
            ------                                     ----------
  (State or Other Jurisdiction of                (I.R.S. Employer I.D. No.
incorporation or organization)


                        1338 South Foothill Blvd. #126
                        Salt Lake City, Utah 84108
                        --------------------------
                 (Address of Principal Executive Offices)

                Issuer's Telephone Number:  (801) 583-9900
                                            --------------

             APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                PROCEEDINGS DURING THE PRECEDING FIVE YEARS

                                     N/A

     Check whether the Registrant filed all documents and reports required to
be filed by Section 12, 13, or 15(d) of the Exchange Act after the
distribution of securities under a plan confirmed by a court.  Yes    No

                   APPLICABLE ONLY TO CORPORATE ISSUERS

     State the number of shares outstanding of each of the Registrant's
classes of common equity, as of the latest practicable date:

                           June 30, 2005

              Common Voting Stock - 10,031,863 shares

Transitional Small Business Disclosure Format (Check one):  Yes X   No


ITEM 1 Financial Statements

          The Financial Statements of the Registrant required to be filed with
this 10-QSB Quarterly Report were prepared by management and commence below,
together with related Notes.  In the opinion of management, the Financial
Statements fairly present the financial condition of the Registrant.
<PAGE>
                 LIPIDVIRO TECH, INC. AND SUBSIDIARY
                 (Formerly Anticline Uranium, Inc.)
                    [A Development Stage Company]

              UNAUDITED CONDENSED FINANCIAL STATEMENTS

                            June 30, 2005
<PAGE>
                 LIPIDVIRO TECH, INC. AND SUBSIDIARY
                 (Formerly Anticline Uranium, Inc.)
                    [A Development Stage Company]
                      Condensed Balance Sheets
                            (Unaudited)

                               ASSETS
                                                          June 30, 2005
Current assets
       Cash                                                $   1,867
                                                           ---------
         Total Current Assets                                  1,867


       Equipment, net                                          2,147

Other Assets
       Definite Life Intangible Assets, net                   33,797
       Goodwill                                              290,318
                                                           ---------
          Total Other Assets                                 324,115
                                                           ---------
TOTAL ASSETS                                               $ 328,129
                                                           =========
               LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
       Accounts Payable                                    $ 155,751
       Shareholder Advances                                  304,800
                                                           ---------
          Total Current Liabilities                          460,551

Stockholders' Equity
       Common stock, authorized 150,000,000 Shares
         Par Value $.001, 10,031,862 shares issued
         and outstanding                                      10,032
       Additional paid in capital                            344,352
       Deficit accumulated during the development stage     (486,806)
                                                           ---------
          Total Stockholders' Equity                        (132,422)
                                                           ---------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY                 $ 328,129
                                                           =========
                     See accompanying notes

<PAGE>                        LipidViro Tech, Inc.
               (Formerly Anticline Uranium, Inc.)
                 [A Development Stage Company]
               Condensed Statements of Operations
                          (Unaudited)

                                        For the Three       For the Six
                                        Months Ended        Months Ended
                                        June 30, 2005       June 30, 2004

Revenue                                   $       0           $       0
Operating Expenses
      General and Administrative Expenses    17,696              12,039
      Research & Development                 54,417              23,575
                                          ---------           ---------
             Total Operating Expenses        72,113              35,614
                                          ---------           ---------
Net Operating (Loss)                        (72,113)            (35,614)

Other income or expense                           0                   0
                                          ---------           ---------
             Total Other Income                   0                   0

Net (Loss)                                $ (72,113)          $ (35,614)
                                          =========           =========

Net (Loss) per Share                      $   (0.01)          $   (0.01)
                                          =========           =========

Weighted Average Number of Shares
Outstanding                              10,031,862          10,031,862
                                         ==========          ==========

                    See the accompanying notes
<PAGE>
                      LipidViro Tech, Inc.
                (Formerly Anticline Uranium, Inc.)
                  [A Development Stage Company]
                Condensed Statements of Operations
                           (Unaudited)

                                      For the Six   For the Six      From
                                        Months        Months      Inception on
                                        Ended         Ended       May 6, 2003
                                     June 30, 2005 June 30, 2004  Through June
                                                                    30, 2005
Revenue                               $       0     $       0     $         0
Operating Expenses
   General and Administrative Expenses   30,011        24,136         183,266
   Research and Development              62,103        48,368         303,563
                                      ---------     ---------     -----------
       Total Operating Expenses          92,114        72,504         486,829
                                      ---------     ---------     -----------
Net Operating (Loss)                    (92,114)      (72,504)       (486,829)

Other income                                  0             0              23
                                      ---------     ---------     -----------
       Total Other Income                     0             0              23

Net (Loss)                            $ (92,114)    $ (72,504)    $  (486,806)
                                      =========     =========     ===========

Net Income per Share                  $   (0.01)    $   (0.01)    $     (0.05)
                                      =========     =========     ===========
Weighted Average Number of Shares
Outstanding                          10,031,862    10,015,469       9,573,169
                                     ==========    ==========     ===========
                     See accompanying notes

<PAGE>
                      LipidViro Tech, Inc.
                (Formerly Anticline Uranium, Inc.)
                  [A Development Stage Company]
                Condensed Statements of Cash Flows
                           (Unaudited)

                                      For the Six   For the Six      From
                                        Months        Months      Inception on
                                        Ended         Ended       May 6, 2003
                                     June 30, 2005 June 30, 2004  Through June
                                                                    30, 2005
Cash Flows from Operating Activities:
  Net (loss)                        $ (92,114)    $ (72,504)    $  (486,806)
  Adjustments to reconcile net loss to
   net cash used for operating activities:
   Depreciation & Amortization             323           278           1,627
   Non-cash expenses and services
   paid by issuance of common stock          0             0             863
   Decrease in Prepaid Expense               0         1,419               0
   (Decrease) in Bank Overdraft         (1,023)            0               0
   (Decrease) Increase in Accounts
   Payable                              (3,312)       26,114         155,752
                                     ---------     ---------     -----------
Net Cash Used by Operating Activities  (96,126)      (44,693)       (328,564)

Cash Flows from Investing Activities:
  Payments for Property and Equipment        0          (960)         (3,263)
  Payments for Definite-Life Intangible
  Assets                                (4,307)       (5,826)        (34,310)
  Payments for Goodwill                      0             0        (269,006)
                                     ---------     ---------     -----------
Net Cash Flows Used for  Investing
Activities                              (4,307)       (6,786)       (306,579)

Cash Flows From Financing Activities:
  Proceeds from Shareholder Advances   102,300        51,500         304,800
  Proceeds from Issuance of Common Stock     0             0         293,700
  Proceeds from Sale of Warrants             0             0          38,510
                                     ---------    ----------     -----------
Net Cash Flows from Financing
Activities                             102,300        51,500         637,010
                                     ---------    ----------     -----------
Net Increase (Decrease) in Cash          1,867            21           1,867

Beginning Cash Balance                       0         3,702               0
                                     ---------    ----------     -----------
Ending Cash Balance                  $   1,867    $    3,723     $     1,867
                                     =========    ==========     ===========
Supplemental disclosure information:
   Cash paid for interest            $       0    $        0     $         0
   Cash paid for income taxes        $       0    $        0     $         0
                     See accompanying notes
<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                  [A Development Stage Company]

  NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1   CONDENSED FINANCIAL STATEMENTS

     The accompanying financial statements have been prepared by the Company
     without audit.  In the opinion of management, all adjustments (which
     include only normal recurring adjustments) necessary to present fairly
     the financial position, results of operations and cash flows at June 30,
     2005 and for the periods then ended have been made.

     Certain information and footnote disclosures normally included in
     financial statements prepared in accordance with generally accepted
     accounting principles in the United States of America have been
     condensed or omitted.  It is suggested that these condensed financial
     statements be read in conjunction with the financial statements and
     notes thereto included in the Company's December 31, 2004 audited
     financial statements.  The results of operations for the periods ended
     June 30, 2005 are not necessarily indicative of the operating results
     for the full year.


NOTE 2 - RELATED PARTY TRANSACTIONS

     Management Compensation - The Company has not paid any cash compensation
     to any officer or director of the Company.  However, in June 2003, the
     Company issued 3,750 shares of common stock to an officer of the Company
     for services rendered valued at $113.

     Office Space - The Company has not had a need to rent office space.  A
     shareholder (former officer) of the Company is allowing the Company to
     use her mailing address, as needed, at no expense to the Company.

     Stock Issuance - In May 2003, in connection with their organization, the
     Company issued 25,000 shares of their previously authorized but unissued
     common stock to an officer of the Company as repayment of organization
     costs of $750, or $.03 per share.

     Shareholder Advances - During the six months ended June 30, 2005,
     shareholders of the Company have advanced $102,300 to the Company to pay
     operating expenses.  As of June 30, 2005, the Company has recorded a
     liability to shareholders of $304,800.  This balance is unsecured, non-
     interest bearing and is payable on demand.

NOTE 3 - GOING CONCERN

     The accompanying financial statements have been prepared in conformity
     with generally accepted accounting principles in the United States of
     America, which contemplate continuation of the Company as a going
     concern.  However, the Company was only recently formed and has not yet
     been successful in establishing profitable operations.  Further, the
     Company has current liabilities in excess of current assets.  These
     factors raise substantial doubt about the ability of the Company to
     continue as a going concern.  In this regard, management is proposing to
     raise any necessary additional funds not provided by operations through
     loans or through additional sales of their common stock.  There is no
     assurance that the Company will be successful in raising this additional
     capital or in achieving profitable operations.  The financial statements
     do not include any adjustments that might result from the outcome of
     these uncertainties.

<PAGE>
               LIPIDVIRO TECH, INC. AND SUBSIDIARY
                (Formerly Anticline Uranium, Inc.)
                  [A Development Stage Company]

  NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS


NOTE 4 - COMMITMENTS AND CONTINGENCIES

     Agreements - In August 2004, the Company signed a one-year agreement for
     the use of a research facility and staff to conduct research on behalf
     of the Company and to have a researcher coordinate the activities.  The
     Company agreed to pay up to $600,000 for supplies, facilities, a
     laboratory technician and coordination efforts. From January 31, 2005
     through June 30, 2005, the Company has paid a total of $60,000 under
     this agreement. From the start of this contract the Company has paid a
     total of $65,000.

     In May 2005, the Company signed a six-month agreement to have a
     researcher coordinate the research activities.  The Company agreed to
     pay $30,000 for the coordination efforts.  Through June 30, 2005, the
     Company has paid a total of $10,000 under this agreement.  During the
     six months ended June 30, 2005, the Company also paid an additional
     $5,000 on a previous contract.

<PAGE>
ITEM 2 Management Discussion and Analysis or Plan of Operation

Plan of Operation.
------------------

Overview.
---------

     LipidViro Tech, Inc. is a development-stage biotechnology company engaged
in developing drug products, fluid purification processes, and drug production
and delivery systems (DPD System). Utilizing the Company's proprietary DPD
System, LipidViro is currently developing two products for commercialization;
therapeutic treatments for Cardiovascular diseases, and processes to
inactivate virus, bacteria and prions producing pathogen-free biological
products.


Technology.
-----------

     LipidViro's technology is based on three components:

     *    Our proprietary Drug Production and Delivery System (LipidViro DPD
          System) which produces and delivers a precise, measured dose of
          ozone;

     *    Our proprietary Gas-Fluid Exchange Device (GFE Device) which
          efficiently mixes ozone with a fluid; and,

     *    Our proprietary methods that utilize precise, measured dosages of
          ozone (LVT3), to treat disease and purify bio-fluids.

The Company has applied for patent protection on all aspects of this
technology.

While medicinal ozone therapies have been used for decades in European
countries, the FDA rejected applications to develop ozone as a drug in the
United States. The common reason underlying these repeated failures was poor
measuring and mixing techniques and the inability to produce and deliver ozone
in precise, measured dosages.

LipidViro's proprietary ozone Drug Production and Delivery System (DPD System)
solve both of these problems. The LipidViro DPD System produces a precise,
measured dose of ozone, accurate within 2% of the total dose. The technology
behind the DPD system allows for a precise, standardized treatment to be
delivered by any clinician throughout the world. The LipidViro GFE Device
efficiently mixes ozone with a fluid by achieving superior surface area
contact between the gas and the fluid. The LipidViro GFE Device produces
efficient, controlled, consistent, and reproducible mixing, allowing for
reliable, repeatable ozone delivery, maximizing treatment results.

We believe Lipidviro's technology provides the first and only process able to
deliver precise, measured doses of ozone that are consistent and reproducible.
We believe this proprietary technology establishes LipidViro as the exclusive
market leader, with the only process capable of achieving regulatory approval
for use of ozone as a drug.

2005 Milestones and Operational Plan.
-------------------------------------

     Corporate Development.  Our corporate operations objectives for 2005
include financing operations, establishing corporate governance sufficient to
apply for NASDAQ SM cap or AMEX listing and, developing and implementing a
public relations strategy to enhance shareholder liquidity and value.

     Scientific Agenda.  Our scientific agenda for 2005 includes, site
selection and contracting for initial cardiovascular clinical trials; design
and initiate cardiovascular clinical trials to produce pilot data; and,
selection of a strategic partner for sera purification.

     Technology Development.  Our technology agenda for 2005 includes:
selecting a strategic partner to produce our Drug Production and Delivery
System; and, selecting a strategic partner to manufacture our Contact Device.

     Financing.  We require immediate financing to fund operations for the
next 12 months, including our described technology and corporate development
and our scientific agenda.  During fiscal year 2005 we will attempt to raise
$3-7 million dollars from equity, debt and grants, which we believe will
sufficiently sustain our projected operations through the end of fiscal '06.
We will attempt to raise additional money from the exercise of the Company's
Class A and B warrants during June of '06.  If fully exercised, these warrants
could raise an additional $28 million. We do not have sufficient cash on hand
to finance our current plan of operation.  Since inception, debt and equity
financing have funded all operations including research expenses. We expend
and will likely continue to expend substantial funds to complete our research,
development and operational objectives.  To fund these operations we will
consider all options available.  Consequently, now and on an ongoing basis we
will consider raising capital through collaborative arrangements, strategic
alliances, research grants or equity and debt financings or from other
sources.

2005 Pre-Clinical Laboratory Research, Product Development.
-----------------------------------------------------------

     Our pre-clinical, product development research is designed to evaluate
our proprietary technology and process. We utilize the results of our pre-
clinical research studies to identify potential products.  Each potential
product is ranked for development priority based on our assessment of the
product's prospects for commercial success. Our evaluation includes studying
the efficacy and toxicity of LVT3 in-vitro, the time, expense and anticipated
regulatory hurdles likely required to reach commercialization, and,
competition in that product category.

     Early research suggests our proprietary technology and process possess a
capacity to inactivate viruses and treat cardiovascular diseases.  While our
research is preliminary and incomplete, and will require additional research
to verify, it does suggest the potential for multiple products that we believe
are worthy of further investigation.   Product categories we are evaluating
include: (i) processing biologicals for pathogen removal and purification;
(ii) developing therapeutics to treat serious infectious diseases; (iii)
developing therapeutics for treating lipid associated diseases; and, (iv)
developing treatments for cardiovascular, neurological and inflammatory
diseases.

Biological Fluid Purification.  During the first fiscal quarter 2005, we
initiated discussion for development of a commercial bio-fluid purification
process with several commercial bio-fluid manufacturers.  These discussions
are ongoing at this time.  During the second fiscal quarter the Company
commenced collaboration with a commercial sera manufacturer to develop a
bovine sera product that can be labeled free of prion infectivity.  This
project includes evaluation of sera bio-function post treatment and design of
validation studies in cooperation with the USDA.  These steps may be
characterized as due diligence on behalf of the sera manufacturer, who has
committed product and resources to the project.

Prion Research.  During the first fiscal quarter, on March 3, 2005 the Company
announced pre-clinical research results which demonstrated the ability to
substantially inactivate infectious prion proteins in bovine serum.
LipidViro's proprietary technology reduced prion infectivity in bovine serum
below the limits of detection by both cell and Western blot assays; two gold
standards for prion detection. During the second fiscal quarter, these data
were presented at the Meeting of the International Union of Microbiological
Societies, San Francisco.  Also during the second quarter, we designed and
initiated dose-ranging studies to help identify optimal dosages demonstrating
prion inactivation.  These studies are ongoing.

Clinical Trials.  During the first fiscal quarter of 2005, we continued
development and design of pre-clinical studies associated with our
Cardiovascular and Neurological Platform. Our objective is to initiate
clinical studies during 2005.  During the second fiscal quarter we applied for
NIH funding of our first proposed clinical studies.

Intellectual Property.  We have filed for patent protection covering our LVT3
drug production and delivery technology and, our GEN-1, GEN-2 GEN-3 and GEN-4H
drug delivery devices, and for proprietary applications utilized by our
process.


ITEM 3 CONTROLS AND PROCEDURES

     As of the end of the period covered by this Quarterly Report, we carried
out an evaluation, under the supervision and with the participation of our
President, of the effectiveness of our disclosure controls and procedures.
Based on this evaluation, our President concluded that our disclosure controls
and procedures are effectively designed to ensure that information required to
be disclosed or filed by us is recorded, processed or summarized, within the
time periods specified in the rules and regulations of the Securities and
Exchange Commission.  It should be noted that the design of any system of
controls is based in part upon certain assumptions about the likelihood of
future events, and there can be no assurance that any design will succeed in
achieving its stated goals under all potential future conditions, regardless
of how remote.

In addition, we reviewed our internal controls over financial reporting, and
there have been no changes in our internal controls or in other factors in the
last fiscal quarter that has materially affected or is reasonably likely to
materially affect our internal control over financial reporting.

                   PART II - OTHER INFORMATION

Item 1.   Legal Proceedings.
          ------------------

          None; not applicable.

Item 2.   Unregistered Sales of Equity Securities and Use of Proceeds.
          ------------------------------------------------------------

          None; not applicable.

Item 3.   Defaults Upon Senior Securities.
          --------------------------------

          None; not applicable.

Item 4.   Submission of Matters to a Vote of Security Holders.
          ----------------------------------------------------

          None; not applicable.

Item 5.   Other Information.
          ------------------

          None; not applicable

Item 6.   Exhibits.
          ---------

          Exhibits.

          31 302 Certification of Kenneth P. Hamik

          32 906 Certification


                            SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.

                                     LIPIDVIRO TECH, INC.


Date: 8/15/2005                    By/s/Kenneth P. Hamik
      --------------                 -------------------
                                     Kenneth P. Hamik
                                     President, CFO and Director